ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
123.432,12
-0,50%
S&P 500
6.039,31
-0,47%
US Dollar vs BRL
5,8576
0,00%
Bitcoin
103.846,06
2,48%
Brent Oil
75,855
-0,99%
As Melhores Corretoras Online
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. ImmunityBio Inc (IBRX)

  7. ImmunityBio Inc (IBRX) Notícias

IBRX

ImmunityBio (IBRX)

ImmunityBio Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:IBRX
DataHoraFonteTítuloCódigoCompanhia
29/01/202510:30Business WireImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung CancerNASDAQ:IBRXImmunityBio Inc
27/01/202511:00Business WireImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In SituNASDAQ:IBRXImmunityBio Inc
24/01/202522:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
15/01/202519:20Business WireImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the AgencyNASDAQ:IBRXImmunityBio Inc
15/01/202519:20Business WireImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United KingdomNASDAQ:IBRXImmunityBio Inc
06/01/202511:00Business WireImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now EffectiveNASDAQ:IBRXImmunityBio Inc
12/12/202410:00GlobeNewswire Inc.D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public OfferingNASDAQ:IBRXImmunityBio Inc
12/12/202408:45Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IBRXImmunityBio Inc
11/12/202409:46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IBRXImmunityBio Inc
11/12/202409:30Business WireImmunityBio, Inc. Announces Pricing of Public Offering of Common StockNASDAQ:IBRXImmunityBio Inc
10/12/202418:24Business WireImmunityBio, Inc. Announces Proposed Public Offering of Common StockNASDAQ:IBRXImmunityBio Inc
21/11/202412:00PR Newswire (US)ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data FulfillmentNASDAQ:IBRXImmunityBio Inc
19/11/202411:00PR Newswire (US)ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False StatementsNASDAQ:IBRXImmunityBio Inc
19/11/202410:00Business WireImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 MonthsNASDAQ:IBRXImmunityBio Inc
12/11/202409:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IBRXImmunityBio Inc
12/11/202409:15Business WireImmunityBio Reports Third-Quarter 2024 Financial ResultsNASDAQ:IBRXImmunityBio Inc
24/10/202410:00Business WireFirst Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin LymphomaNASDAQ:IBRXImmunityBio Inc
21/10/202410:00Business WireImmunityBio to Participate in the Jefferies London Healthcare ConferenceNASDAQ:IBRXImmunityBio Inc
09/09/202409:30Business WireImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer NASDAQ:IBRXImmunityBio Inc
12/08/202409:46Business WireImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA ApprovalNASDAQ:IBRXImmunityBio Inc
06/08/202410:00Business WireImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial CancerNASDAQ:IBRXImmunityBio Inc
25/07/202412:02PR Newswire (US)Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law FirmNASDAQ:IBRXImmunityBio Inc
20/06/202410:00Business WireImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint InhibitorsNASDAQ:IBRXImmunityBio Inc
07/06/202410:13Business WireImmunityBio Announces 2024 Annual Meeting of Stockholders with Company UpdateNASDAQ:IBRXImmunityBio Inc
17/05/202410:00Business WireConnecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday PodcastNASDAQ:IBRXImmunityBio Inc
07/05/202409:00Business WireImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®NASDAQ:IBRXImmunityBio Inc
02/05/202417:04Business WireImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer TypesNASDAQ:IBRXImmunityBio Inc
30/04/202409:00Business WireImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological AssociationNASDAQ:IBRXImmunityBio Inc
25/04/202401:03Business WireImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung CancerNASDAQ:IBRXImmunityBio Inc
22/04/202422:56Business WireImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder CancerNASDAQ:IBRXImmunityBio Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:IBRX

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
AGXY3
Agrogalaxy Participacoes ON
BOV
RCSL4
RECRUSUL PN
BOV
AZEV4
AZEVEDO PN
BOV
TELB4
TELEBRAS PN
BOV
FICT3
Fictor Alimentos ON
BOV
PRIO3
PETRORIO ON
BOV
VVEO3
CM Hospitalar ON
BOV
PMAM3
PARANAPANEMA ON
BOV
GFSA3
GAFISA ON
BOV
COGN3
COGNA ON
BOV
RCSL3
RECRUSUL ON
BOV
RAIZ4
Raizen S.A PN
BOV
INTB3
Intelbras S.A ON
BOV
BRAV3
Brava Energia ON
BOV
BHIA3
Grupo Casas Bahia ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios